Showing posts with label netanyahu. Show all posts
Showing posts with label netanyahu. Show all posts

Monday, May 11, 2026

Netanyahu's 8th Front

HOW TO CURE EVERYTHING: risk-rewards will massively change once Cell Cinema scales I keep coming back to one question: what becomes worth attempting when biology becomes easier to read? Most conversations about AI and drug discovery are still stuck on generation. ............. But the deeper shift happens when the biological feedback loop becomes fast and information-rich enough that those generated ideas can be corrected by reality. ................

This is one reason software compounds so quickly.

................ In biology, the feedback loop has been slow, expensive, destructive, and often indirect. It involves: perturbing a system, waiting, stop experiment, stain it, sequence it, image it, or run an endpoint assay, and then reconstruct what you think happened. Sometimes that works. Sometimes the most important part of the biology happened in between the timepoints, in a cell state you did not measure, through a compensatory pathway you did not expect, or in a form of toxicity that only becomes obvious when the system is watched over time. ........ Cell Cinema is what changes when that feedback loop starts to look more like a movie and less like an autopsy. ............... The real point is that living cells move through states, and many of the most important drug effects are not static. ................ If you only ask one question at one timepoint, you get one kind of answer. If you watch many dimensions of the same living system over time, you get Cell Cinema. .............

Drug discovery has always had a strange risk-reward shape.

.................. The reward for being right is enormous. A successful drug can change the standard of care for a disease, create a generational company, and alter the lives of millions of people. But the risk of being wrong is also enormous, because you often find out late. You can spend years building conviction around a target, molecule, indication, and mechanism, only to discover in humans that the biology did not translate, the drug was toxic, the effect was too weak, or the disease was not being modulated in the way your model implied. .................... When the cost of being wrong is catastrophic, rational people cluster around validated biology, known modalities, precedent, and mechanisms that have already survived some contact with the clinic. The industry says it wants novelty, but structurally it punishes novelty whenever the measurement layer cannot make that novelty legible. Only one thing can change this: readout. ................. The first wave is simple derisking. This is the least glamorous part and probably the most commercially important place to begin. If a drug has toxicity, off-target effects, or an ugly cellular phenotype, I want us to find that earlier. About 60-70% of a 90% failure rate in drug discovery are clustered around tox and off-target effects. ..................... Cell Cinema sees them as (1) live, and (2) high-dimensional vectors. This matters. Cells do not simply jump from healthy to dead, instead they often are benefitted by evolution, and compensate, adapt, fail, recover, or enter intermediate states. A destructive endpoint assay can miss those trajectories because it collapses the process into a final measurement. A living readout can show the path where a lot of the truth is; in biology, this truth is simply too high-dimensional for anything other than a GPU. ................. the problem starts scaling. Intelligence, too cheap to meter. That scale creates the highest impact: behavioral. ............

at No comments:
Labels: ,
Subscribe to: Posts (Atom)